Active	Status	Sponsor type	Region	Phase	Filter
3 Active 8 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
GCS 100 IV / Innoviva
ChiCTR-TRC-12002980: A randomized double-blind multicenter phase III study of Pegylated Human G-CSFin patients receiving myelosuppressive chemotherapy	Completed	3	510		GCSF 5ug/kg ;PEG-GCSF100ug/kg ;PEG-GCSF 6mg	Cancer Hospital of Chinese Academy of Medical Sciences; None, QILU PHARMACEUTICAL CO.LTD	Chemotherapy-induced neutropenia
2008-004087-40: A Phase 2 Study of GCS-100 in Combination with Chemo-immunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Ongoing	2	28	Europe	GCS-100, GCS-100,	Prospect Therapeutics, Inc	Relapsed or refractory diffuse large B-cell lymphoma
ChiCTR-TRC-12002499: Pharmacokinetics and Pharmacodynamics of Pegylated Human G-CSF	Completed	1/2	44		PEG-GCSF 60ug/kg ;PEG-GCSF100ug/kg ;PEG-GCSF 120ug/kg ;G-CSF 5ug/kg	Affiliated Beijing Chest Hospital of Capital Medical University; Beijing Chest Hospital, Capital Medical University, QILU PHARMACEUTICAL CO., LTD.	Chemotherapy-induced neutropenia